



Atty. Dkt. No. 355908-3303

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony E. BOLTON, et al
Title: PEPTIDE-CARRYING BODIES
FOR IMMUNE RESPONSE
Appl. No.: 10/502,149
Filing Date: 7/19/2004
Examiner: Not Yet Assigned
Art Unit: Not Yet Assigned

<p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p><u>Rene Campos</u> (Printed Name)</p> <p><u>[Signature]</u> (Signature)</p> <p><u>11.9.04</u> (Date of Deposit)</p>
--

TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents in the above-identified application.

1. First Information Disclosure Statement (2 pgs.);
2. PTO Form 1449 (1 pg.);
3. Seven (7) references as cited on PTO Form 1449 (B1 and C1-C6); and
4. Return postcard.

[X] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such

extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to
Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address
indicated below.

Respectfully submitted,

Date 11-9-04

By Gerald F. Swiss

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 251-1103
Facsimile: (650) 856-3710

Gerald F. Swiss
Attorney for Applicant
Registration No. 30,133



DT03 d PCT/PTO 12 NOV 2004

Atty. Dkt. No. 355908-3303

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony E. BOLTON, et al


Title: PEPTIDE-CARRYING BODIES
FOR IMMUNE RESPONSE

Appl. No.: 10/502,149

Filing Date: 7/19/2004

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

<p align="center">CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.</p> <p align="center"><u>Rene Campos</u> (Printed Name)</p> <p align="center"><u></u> (Signature)</p> <p align="center"><u>11. 9. 04</u> (Date of Deposit)</p>
--

FIRST INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date 11-9-04

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 251-1103
Facsimile: (650) 856-3710

By Gerald F. Swiss
Gerald F. Swiss
Attorney for Applicant
Registration No. 30,113

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

355908-3303

SERIAL NO.

10/502,149

APPLICANT

Anthony E. BOLTON, et al

FILING DATE

7/19/2004

GROUP ART UNIT

Not Yet Assigned

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	B1	WO01/66785	9/13/2001	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Fadok et al. "A receptor for phosphatidylserine-specific clearance of apoptotic cells" <i>Nature</i> 405:85-90 (2000)
	C2	Scott, Rona, et al. "Phagocytosis and clearance of apoptotic cells is mediated by MER" <i>Nature</i> 411:207 (2001)
	C3	Griffin, WST, et al. "Brain interleukin 1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer Disease" <i>Proceedings of the National Academy of Sciences USA</i> 86:7611-7615 (1989)
	C4	Mogi, M. Interleukin (IL)-1 beta, IL-1, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's Disease" <i>Neuroscience Letters</i> 211:13-16 (1996)
	C5	Murray et al. "Evidence that increase hippocampal expression of the cytokine interleukin-1 β is a common trigger for age and stress-induced impairments in long-term potentiation" <i>J. Neuroscience</i> 18:2974-2981 (1998)
	C6	Bliss et al. "A synaptic model of memory: long-term potentiation in the hippocampus" <i>Nature</i> 361:31-39 (1993)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.